Table 1.
Summary of patient and transplant characteristics.
| Number of patients | |
|---|---|
| Sex | |
| Male | 23 |
| Female | 7 |
| Inheritance | |
| X-linked | 14 |
| AR | 12 |
| Missing data | 4 |
| Donor | |
| MSD | 8 |
| 10/10 UD | 13 |
| 9/10 UD | 8 |
| Haploidentical | 1 |
| Conditioning | |
| Busulfan, fludarabine | 21 |
| Busulfan, cyclophosphamide | 1 |
| Treosulfan, fludarabine | 3 |
| Treosulfan, thiotepa, fludarabine | 5 |
| Serotherapy | |
| ATG | 11 |
| Alemtuzumab | 15 |
| No | 4 |
| In-vitro T-cell depletion | |
| No | 25 |
| TCRαβ/CD19 depletion | 2 |
| CD45 RA+ depletion | 1 |
| Partial CD3 depletion | 2 |
| Stem cell source | |
| Bone marrow | 23 |
| Peripheral blood | 7 |
AR, autosomal recessive; MSD, matched sibling donor; UD, unrelated donor; ATG, antithymocyte globulin.